Metronidazole Basi (Metronidazole)

The drug enters anaerobic microorganisms and is reduced by intracellular electron‑transfer proteins. This reduction creates reactive nitro‑radical intermediates that bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, which leads to microbial cell death.

The prescribed dose is set by the treating clinician based on the type and severity of infection, patient weight, renal and hepatic function, and local treatment guidelines. No fixed regimen is provided here.

Pregnancy safety data are limited and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Metronidazole offers a broad spectrum against obligate anaerobes and certain protozoa, often preferred for its oral and IV formulations. Alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations may be used, but Metronidazole typically has fewer drug‑interaction concerns and a well‑established safety profile.

Store the intravenous solution at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect from light, and do not freeze or shake the container.

Metronidazole Basi is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescriber according to the infection being treated and patient tolerance.

Serious adverse events include seizures, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and peripheral neuropathy. Patients should be monitored for neurological symptoms, rash, or signs of hypersensitivity, and therapy should be stopped immediately if these occur.

Individuals with a known hypersensitivity to metronidazole or other nitroimidazoles should avoid the product. Caution is also advised for patients with severe hepatic impairment, and it should be used only when clearly indicated in early pregnancy.